SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Navarro, Miguel; Porras, Ignacio; Hernando, Jorge; Maurente Oliveira, Eduardo; Jimenez Fonseca, Paula; Martinez-Trufero, Javier; Rubió-Casadevall, Jordi

View

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023), 2024 (2.022Mb)

Author

Navarro, Miguel

Porras, Ignacio

Hernando, Jorge

Maurente Oliveira, Eduardo

Jimenez Fonseca, Paula

Martinez-Trufero, Javier

Rubió-Casadevall, Jordi

Date

2024-11

Permanent link

https://hdl.handle.net/11351/12167

DOI

10.1007/s12094-024-03736-6

ISSN

1699-3055

WOS

001324609600001

PMID

39325263

Show full item record

Abstract

Thyroid cancer (TC) represents 3% of global cancer incidence. Recent changes have optimized treatment decisions based on risk assessment, molecular profiling, and imaging assessment, leading the development of targeted agents that have modified the natural history of this disease. This increasing complexity on treatment options requires careful assessment at the different stages of the disease to provide the most suitable approach from diagnosis to long-term follow-up. This guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management.

Keywords

Thyroid carcinoma; Molecular alterations; Systemic treatment

Bibliographic citation

Alonso-Gordoa T, Jimenez-Fonseca P, Martinez-Trufero J, Navarro M, Porras I, Rubió-Casadevall J, et al. SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023). Clin Transl Oncol. 2024 Nov;26:2902–16.